Abstract
Introduction: Meningiomas account for over 30% of all primary brain tumors. While surgery can be curative for these tumors, several factors, including higher histological grade and a higher Simpson grade of resection, may lead to a higher likelihood of recurrence. For recurrent meningiomas, particularly if additional radiation and microsurgical resection options have been exhausted, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, may be considered as a therapeutic agent. However, the literature regarding the effects of bevacizumab for patients with meningioma recurrences is sparse. Thus, we present a systematic review of the literature and case series of patients from our institution with recalcitrant meningiomas who were subsequently treated with bevacizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
